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A B S T R A C T
Studies using animal models have demonstrated that ingestion of bovine lactoferrin (bLF)
is able to induce cytokine expression in the intestine and inhibit carcinogenesis in the colon
and other organs of experimental animals. Consequently, a clinical trial was conducted in
the National Cancer Center Hospital, Tokyo, Japan to determine whether ingestion of bLF
affected the growth of colorectal polyps in humans. The Tokyo-trial found that ingestion
of 3.0 g bLF suppressed the growth of colorectal polyps and increased the level of serum
human lactoferrin in participants 63 years old or younger. The present study is a comple-
mentary study to the Tokyo-trial to determine if a change in the expression of one or more
cytokines could be detected in the colon of the Tokyo-trial participants after ingesting bLF.
We found that daily ingestion of 3.0 g bLF promoted the expression of interferon alpha in
the colon of the Tokyo-trial participants.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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1. Introduction
Milk is a rich source of bioactive peptides (Korhonen, 2009).
Lactoferrin is an approximately 80 kDa iron-binding glycopro-
tein present in the milk of most mammalian species. In 1995,
McIntosh et al. reported that the whey fraction of bovine milk,
which contains lactoferrin, protects against the development
of intestinal cancers in rats (McIntosh, Regester, Le Leu, Royle,
& Smithers, 1995). Since that time, several studies using animal
models have demonstrated that ingestion of bovine lactoferrin
(bLF) is able to induce cytokine expression in the intestine and
inhibit carcinogenesis in the colon and other organs of ex-
perimental animals (Iigo et al., 2009; Tsuda et al., 2010).
As a result of these studies, a randomized, controlled clini-
cal trial beginning in 2002 and ending in 2006 was conducted
in the National Cancer Center Hospital, Tokyo, Japan to deter-
mine whether ingestion of bLF had an effect on the growth of
colorectal polyps in humans; this trial is reported by Kozu et al.
(2009). Briefly, trial participants ingested 0, 1.5, or 3.0 g bLF daily
for 1 year.The size of adenomatous colorectal polyps,T-cell sub-
population numbers, natural killer cell activity and number,
neutrophil number, and the serum levels of interleukin-18,
interferon-gamma, and human lactoferrin (hLF) were mea-
sured. The Tokyo-trial reported that ingestion of 1.5 g bLF had
no significant effect on any of the parameters measured;
however, ingestion of 3.0 g bLF had two significant effects: (i)
the growth of colorectal polyps was inhibited in trial partici-
pants 63 years old or younger and (ii) the level of hLF in the
serumwas increased in trial participants 63 years old or younger
(Kozu et al., 2009).The authors of theTokyo-trial concluded that
ingestion of bLF inhibited the growth of adenomatous colon
polyps and probably acted via modulation of immune system
function.
The present study is a complementary study to the Tokyo-
trial. The purpose of this ancillary study was to determine if
a change in the expression of one or more cytokines could be
detected in the colon of the Tokyo-trial participants who in-
gested bLF for 1 year. In the Tokyo-trial, normal tissue samples
were collected from the trial participants before the trial began
and after the trial ended. The present ancillary study exam-
ined the RNA extracted from these tissue samples.We found
that ingestion of bLF promoted the expression of interferon
alpha (IFNA) in the colon of the Tokyo-trial participants.
2. Methods
2.1. The Tokyo-trial
A blinded, randomized, controlled clinical trial beginning in 2002
and ending in 2006 was conducted in the National Cancer
Center Hospital,Tokyo, Japan to determine if ingestion of bovine
lactoferrin (bLF) would inhibit the growth of precancerous,
adenomatous colorectal polyps in human patients. Trial par-
ticipants took six tablets daily containing 0, 250, or 500 mg bLF.
The bLF was approximately 10–20% iron saturated.The tablets
also contained carbohydrate (D-sorbitol, maltitol, and corn
starch) but not fat or dietary fiber and had a caloric value of
36 kcal. The tables were indistinguishable from each other in
appearance, smell, and taste.There were no adverse effects as-
sociated with ingestion of bLF or the placebo. A description of
the Tokyo-trail design, participants, interventions, outcomes,
sample size, randomization, blinding, statistical methods, char-
acteristics of the intent-to-treat population at the commence-
ment of the trial, and the CONSORT flowchart are presented
in Kozu et al. (2009).
2.2. Ethics statement
TheTokyo-trial was initiated after approval by the Ethical Com-
mittee of the National Cancer Center Hospital,Tokyo, Japan and
is registered in the University Hospital Medical Information
Network Clinical Trials Registry (UMIN-CTR; http://
www.umin.ac.jp/ctr/index.htm) Tokyo, Japan, number
C000000182. All trial participants provided written informed
consent.
2.3. Collection of RNA samples for analysis
Prior to the start of the Tokyo-trial and at the end of the trial,
a small tissue sample was collected from normal mucosa close
to the target polyp; also at the end of the trial, the target polyps
(and all other growths detected) were removed. Target polyps
and tissue sample sites were located at the most proximal sites
of the right colon (cecum to transverse colon) and the left colon
(descending colon to rectum). Tissue and polyp samples were
immediately transferred to the laboratory on ice and divided
into halves; one half was used for histological analysis and RNA
was extracted from the other half. RNA was extracted using
the Isogen (Wako) extraction protocol according to the manu-
facturer’s instructions. RNA was extracted immediately after
obtaining the tissue specimens and then stored at −80 °C until
use. RNA integrity was checked with anAgilent 2100 Bioanalyzer
using an RNA Pico chip. RIN numbers weremostly 5.8 or greater:
in these samples the TaqMan Real Time PCR cycle threshold
of actin was 32 or less. In some samples, the RIN number was
below 5.8: in these samplesTaqMan Real Time PCR did not gen-
erate an actin signal. These samples are labeled NA (No Actin)
in Tables 1–3, and Supplementary Table S2. In the present study
we used only normal tissue samples, which were collected both
at the beginning and at the end of the trial, for analysis of gene
expression.
2.4. RNA analysis
RNA extracts were treated with DNase (Takara) and reverse tran-
scribed using PrimeScript reverse transcriptase (Takara) with
random hexamers (Invitrogen) and RNase OUT (Invitrogen) ac-
cording to the manufacturers’ instructions. Reverse
transcriptase-negative controls were performed for all samples
and cDNA-negative controls were performed for all primer pairs.
All reverse transcriptase-negative controls and cDNA-negative
controls were negative. A primary screening, using standard
end-point PCR, was performed with samples from the 3.0 g bLF
group. These samples were screened for alpha interferons
(IFNAs), interferon beta (IFNB), interferon gamma (IFNG), IL-
1A, IL-4, IL-7, IL-8, IL-12A, IL-12B, IL-15, IL-18, IL-22, IL-23A, GM-
CSF, and TNF using the primers listed in Supplementary
Table S1. IFNAs, IFNB, IFNG, IL-7, IL-12A, IL-12B, IL15, and IL-
306 j o u rna l o f f un c t i ona l f o od s 1 0 ( 2 0 1 4 ) 3 0 5 – 3 1 7
18 were selected based on reports that these cytokines were
induced in the intestine of mice or rats orally administered bLF
(Iigo et al., 2004, 2009; Kuhara et al., 2000; Kuhara, Yamauchi,
Tamura, & Okamura, 2006; Takakura, Wakabayashi, Yamauchi,
& Takase, 2006; Wakabayashi, Takakura, Yamauchi, & Tamura,
2006; Wang et al., 2000). IL-4 was selected because it is pro-
duced by activated T cells, and ingestion of lactoferrin is re-
ported to activate T cells in the intestine (Spadaro et al., 2007).
IL-22 was selected because it is produced in response to patho-
gens in the gut (Zheng et al., 2008). IL-23A was selected because
it dimerizes with IL-12B to form IL-23. IL-1A was selected
because it is a pleiotropic cytokine involved in various immune
responses. IL-8, GM-CSF and TNF were selected because they
are key cytokines involved in immune cell function. All screen-
ing primers were designed using Primer Premier software
(Premier Biosoft International). IFNA was detected in the ma-
jority of tissue samples while IFNG, IL-1A, IL-4, IL-7, IL-8, IL-
12A, IL-12B, IL-15, IL-18, IL-22, IL-23A, GM-CSF, and TNF were
either not detected or detected in only a small number of tissue
samples. Therefore, all patient samples were screened for the
presence of type I interferons (IFNAs and IFNB) using stan-
dard end-point PCR and the primers listed in Supplementary
Table S1. All screening primers were designed using Primer
Premier software (Premier Biosoft International). PCR-amplicons
were purified using theWizard SV Gel and PCR Clean-Up System
(Promega: Tokyo, Japan) according to the manufacturer’s in-
structions. Purified amplicons were sequenced using a 3130
Genetic Analyzer (Applied Biosystems) according to the manu-
facturer’s instructions. Only IFNA2 and IFNB sequences were
present in most of the samples. Therefore, using the primers
and probes listed in Supplementary Table S1, TaqMan Real-
Time PCR was used to analyze the relative expression of IFNA
and IFNB with β-actin as an internal control. TaqMan Real-
Time PCR was performed using an Applied Biosystems 7300
Real Time PCR system and PCR primers and TaqMan probes
obtained from Applied Biosystems, according to the manufac-
turer’s instructions.
2.5. Statistics
Differences in the mean values of IFNB and IFNA were ana-
lyzed using the two-tailed Student’s T-test. The distribution of
changes in IFNA gene expression, defined as decrease (≤−2.0
units), no-change (−2.0 to +2.0 units), and increase (≥2.0 units),
was compared between treatment groups based on the
Cochran–Mantel–Haenszel test. Statistical analyses were per-
formed using JMP version 9.0 (SAS Institute Inc, Cary, NC). A
p value of <0.05 was considered to be significant.
3. Results
3.1. Identification of target cytokines
A blinded, randomized, controlled clinical trial beginning in 2002
and ending in 2006 was conducted in the National Cancer
Center Hospital,Tokyo, Japan to determine if ingestion of bovine
lactoferrin (bLF) would inhibit the growth of precancerous,
adenomatous colorectal polyps in human patients. Partici-
pants, randomized into one of three groups, ingested 0, 1.5, or
3.0 g bLF daily for 1 year. There were no adverse effects asso-
ciated with ingestion of bLF or the placebo. The characteris-
tics of the intent-to-treat population at the commencement
of the Tokyo-trial and the CONSORT flowchart of the trial are
presented in Kozu et al. (2009). There were 102 participants in
the per-protocol set (PPS) population of the Tokyo-trial: see
Supplementary Text S1 for a definition of PPS populations and
the reason we used the PPS rather than the full analysis set
(FAS) population samples for the present study. The placebo
group contained 33 participants, the 1.5 g bLF group con-
tained 37 participants, and the 3 g bLF group contained 32 par-
ticipants. Normal tissue samples were obtained from the trial
participants prior to the beginning of the trial and at the end
of the trial, and RNA was extracted and stored at –80 °C. Five
of the participants in the placebo group, six of the partici-
pants in the 1.5 g bLF group, and five of the participants in the
3.0 g bLF group had two target polyps. Therefore, the total
number of samples was 38, 43, and 37 mucosa samples col-
lected before the beginning of the trial and 38, 43, and 37 as-
sociated mucosa samples collected at the end of the trial from
the placebo, 1.5 g bLF, and 3.0 g bLF participants, respectively.
RNA was extracted from each of the samples.
Two sets of screening PCR were performed to identify target
cytokines for further analysis. First, the samples collected from
the 3.0 g bLF group were screened by standard end-point PCR
using the primers indicated in Supplementary Table S1 for ex-
pression of IFNA-1,2,4,5,6,7,8,10,13,14,16,17,21, IFNB, IFNG, IL-
4, IL-7, IL-8, IL-12A, IL-12B, IL-15, IL-18, IL-22, IL-23A, GM-CSF,
and TNF. Expression of these cytokines, with the exception of
IFNA and IFNB, was either not detected or detected in fewer
than 20% of the samples. Therefore, only expression of type I
interferons was examined further. The tissue samples were
screened by standard PCR using the primers indicated in
Supplementary Table S1 for the presence of the different type
I interferons (IFNB and the 13 species of human IFNA (Pestka,
2007)). Because of IFNA redundancy, all of the amplicons gen-
erated by the second screening-PCR were sequenced. IFNA2 was
the most widely detected type I interferon in the samples from
the Tokyo-trial participants (data not shown). The other IFNA
species sequences were either not detected or detected in a
minority of samples. Therefore expression of IFNA2 was ex-
amined by TaqMan Real Time PCR using the primers listed in
Supplementary Table S1. In addition, in this second screen-
ing, IFNB sequences were present in most of the samples, and
therefore, expression of IFNB was also examined.
3.2. Relative expression of IFNB and IFNA
Once target interferon species were identified, we usedTaqMan
PCR to analyze the samples further. Each sample was tested
in quintuplicate for the relative expression of IFNA using β-actin
as an internal control.The relative expression of IFNB and IFNA
is shown in Table 1 (placebo), Table 2 (1.5 g bLF), and Table 3
(3.0 g bLF); these data can be downloaded from Supplementary
Table S2.
A potentially interesting observation, but one which is not
part of this study, is that samples with relatively high IFNB ex-
pression also had relatively high IFNA expression. For example,
samples in which the relative expression of IFNB was greater
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Group Relative IFN levels at the beginning of the trial Relative IFN levels at the end of the trial
IFNB Mean Std Dev IFNA Mean Std Dev IFNB Mean Std Dev IFNA Mean Std Dev
1 54 M L Placebo 0.01 0.03 1.99 0.65 12.50 2.54 84.49 4.42
2 59 M L Placebo 0.00 0.01 52.10 1.75 0.54 1.62 0.00 0.00
2 59 M R Placebo 0.00 0.00 0.08 0.01 2.30 0.64 0.00 0.00
3 58 M R Placebo 0.00 0.00 0.02 0.00 0.05 0.17 1.72 0.66
4 65 M R Placebo 0.00 0.00 91.27 1.42 0.35 0.40 4.59 0.73
5 57 M R Placebo 7.67 1.89 83.71 2.22 0.03 0.08 15.37 2.40
6 70 M R Placebo 0.93 0.11 1.96 0.94 0.00 0.00 96.52 2.47
7 67 M L Placebo 14.05 3.13 100.01 4.32 13.34 1.85 50.79 6.73
8 63 M R Placebo 6.38 0.86 33.77 4.63 1.04 0.41 62.11 1.71
9 73 M L Placebo 0.00 0.00 81.97 0.86 0.00 0.00 1.37 0.14
10 54 M R Placebo 0.05 0.01 0.07 0.03 0.24 0.47 54.21 4.41
11 63 M R Placebo 6.06 2.04 14.92 2.58 0.36 0.37 0.00 0.00
12 70 F L Placebo 7.05 1.61 74.58 4.35 0.12 0.05 12.90 2.53
13 54 F R Placebo 0.92 0.31 4.62 1.14 1.03 0.44 55.51 4.64
14 61 M L Placebo 1.12 0.46 0.00 0.00 0.04 0.02 0.20 0.16
15 71 M R Placebo 4.93 0.84 0.00 0.00 0.00 0.00 63.46 0.98
16 61 M R Placebo 1.34 0.59 19.77 3.47 68.99 0.28 1.77 0.72
17 60 M R Placebo 0.01 0.03 0.67 0.61 6.16 1.41 100.01 4.53
18 72 F L Placebo 29.27 3.01 100.11 7.78 0.25 0.74 62.25 1.01
18 72 F R Placebo 27.20 3.74 104.03 3.48 0.09 0.27 23.78 4.47
19 57 F R Placebo 15.85 3.55 69.34 1.03 0.02 0.03 8.48 1.68
20 46 M L Placebo 0.02 0.06 0.88 0.70 0.00 0.00 71.26 1.81
20 46 M R Placebo 0.13 0.39 55.58 3.42 0.45 0.15 69.24 0.80
21 68 M R Placebo 22.94 4.40 43.82 2.78 0.11 0.33 4.75 0.66
22 60 F R Placebo 99.00 0.24 0.03 0.01 13.81 3.04 99.85 0.23
23 56 M R Placebo 0.06 0.18 7.70 1.35 3.73 0.46 62.19 2.65
24 67 M R Placebo 0.13 0.39 30.24 4.73 27.47 2.38 100.02 7.09
25 66 M L Placebo 6.45 0.23 25.35 4.92 4.70 1.08 77.31 2.28
26 64 M L Placebo 6.93 1.59 6.48 0.91 94.63 0.79 33.40 3.67
27 59 M L Placebo 0.04 0.06 1.77 0.88 0.02 0.06 8.36 0.99
27 59 M R Placebo 0.03 0.01 0.33 0.02 40.29 1.60 100.01 3.14
28 66 M R Placebo 63.40 2.79 0.00 0.00 0.16 0.30 64.70 1.86
29 62 M L Placebo 7.07 1.62 0.98 0.47 15.06 2.59 0.05 0.02
30 75 M L Placebo 20.49 3.95 38.69 7.31 0.04 0.05 3.61 0.74
30 75 M R Placebo 14.37 3.17 93.96 4.28 0.00 0.00 65.40 3.49
31 59 F R Placebo 55.97 3.42 11.58 1.88 10.90 1.86 0.66 0.11
32 68 M R Placebo 0.13 0.03 6.08 0.61 0.46 0.10 0.11 0.02
33 63 M L Placebo 5.56 0.86 22.17 1.65 NA NA NA NA
R: Right colon (cecum to transverse colon).












































Group Relative IFN levels at the beginning of the trial Relative IFN levels at the end of the trial
IFNB Mean Std Dev IFNA Mean Std Dev IFNB Mean Std Dev IFNA Mean Std Dev
34 67 M R 1.5 g bLF 0.61 1.86 0.00 0.00 20.78 2.63 100.06 2.34
35 70 M R 1.5 g bLF 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.00
36 60 F R 1.5 g bLF 0.23 0.70 0.00 0.00 4.61 1.02 0.00 0.00
37 75 M R 1.5 g bLF 10.26 0.64 104.87 2.34 0.03 0.05 31.92 1.94
38 55 M L 1.5 g bLF 0.00 0.00 0.02 0.00 12.70 1.27 69.90 1.93
39 51 M R 1.5 g bLF 11.50 0.99 0.00 0.00 46.17 0.29 120.31 4.85
40 70 M L 1.5 g bLF 0.06 0.10 10.50 1.91 0.00 0.00 60.70 4.26
41 61 M R 1.5 g bLF 0.03 0.01 0.05 0.01 6.04 1.34 66.69 4.93
42 74 M R 1.5 g bLF 0.03 0.10 0.01 0.00 11.45 0.41 0.00 0.00
43 51 M R 1.5 g bLF 0.00 0.00 0.00 0.00 2.71 0.62 0.01 0.02
44 63 M R 1.5 g bLF 108.59 1.41 72.53 4.40 0.00 0.00 0.00 0.00
45 48 M R 1.5 g bLF 0.00 0.00 62.91 4.95 10.60 1.18 101.05 4.84
46 61 M L 1.5 g bLF 0.18 0.32 22.15 3.69 5.80 1.17 0.00 0.00
46 61 M R 1.5 g bLF 58.12 1.55 0.00 0.00 0.05 0.09 0.00 0.00
47 56 M R 1.5 g bLF 0.54 0.33 0.00 0.00 0.55 0.16 52.11 6.35
48 71 F L 1.5 g bLF 12.70 1.04 1.54 0.35 98.18 2.31 100.01 3.85
48 71 F R 1.5 g bLF 9.57 0.90 132.39 3.94 6.00 1.33 102.25 4.71
49 64 F R 1.5 g bLF 12.91 2.49 100.76 2.53 0.12 0.36 81.14 6.02
50 55 F L 1.5 g bLF 0.03 0.08 0.00 0.00 0.01 0.03 0.00 0.00
51 46 M R 1.5 g bLF 62.36 1.34 0.01 0.00 0.14 0.10 100.03 0.75
52 63 M R 1.5 g bLF 18.57 1.30 96.71 4.71 2.96 0.63 0.00 0.00
53 66 M L 1.5 g bLF 0.89 0.33 0.00 0.00 127.43 1.00 85.69 11.47
53 66 M R 1.5 g bLF 0.30 0.11 60.01 1.73 28.27 3.96 100.11 2.65
54 65 M R 1.5 g bLF 0.50 0.03 14.65 0.90 16.92 1.38 103.09 15.49
55 57 M R 1.5 g bLF 0.06 0.08 0.00 0.00 12.43 2.81 100.20 0.40
56 64 M R 1.5 g bLF 0.02 0.05 0.00 0.00 12.49 2.37 91.79 6.14
57 61 M R 1.5 g bLF 102.20 1.47 0.00 0.00 15.16 1.47 0.00 0.00
58 61 F R 1.5 g bLF 102.17 1.37 77.79 2.49 3.95 0.79 0.00 0.00
59 64 M L 1.5 g bLF 40.81 1.73 75.52 5.94 0.01 0.02 0.00 0.00
60 74 M R 1.5 g bLF 0.00 0.00 0.00 0.00 4.24 0.94 1.19 0.24
61 61 M L 1.5 g bLF 82.92 1.03 0.00 0.00 0.80 0.96 0.00 0.00
62 66 M R 1.5 g bLF 5.49 1.24 0.00 0.00 5.29 1.17 0.00 0.00
63 64 F R 1.5 g bLF 0.76 0.99 0.00 0.00 0.00 0.00 60.33 0.97
64 53 M L 1.5 g bLF 69.77 0.30 64.16 2.09 0.09 0.16 53.95 5.53
64 53 M R 1.5 g bLF 0.00 0.00 100.55 1.14 3.86 0.85 78.26 4.99
65 67 M L 1.5 g bLF 96.42 0.81 96.86 6.64 NA NA NA NA
66 50 M L 1.5 g bLF 0.08 0.10 0.00 0.00 NA NA NA NA
67 61 F R 1.5 g bLF 129.20 2.03 80.56 1.92 NA NA NA NA
44 63 M L 1.5 g bLF NA NA NA NA 3.09 0.67 80.96 3.88
68 64 F L 1.5 g bLF NA NA NA NA 2.00 0.46 0.00 0.00
69 57 M R 1.5 g bLF NA NA NA NA NA NA NA NA
70 54 M L 1.5 g bLF NA NA NA NA NA NA NA NA
70 54 M R 1.5 g bLF NA NA NA NA NA NA NA NA
R: Right colon (cecum to transverse colon).












































Group Relative IFN levels at the beginning of the trial Relative IFN levels at the end of the trial
IFNB Mean Std Dev IFNA Mean Std Dev IFNB Mean Std Dev IFNA Mean Std Dev
71 69 M R 3.0 g bLF 0.00 0.00 0.30 0.09 0.00 0.00 55.85 9.20
72 58 F R 3.0 g bLF 0.00 0.00 1.27 0.24 0.13 0.25 42.65 6.52
73 60 M R 3.0 g bLF 0.07 0.12 0.00 0.00 0.00 0.00 42.63 7.31
74 59 M R 3.0 g bLF 0.23 0.70 40.22 5.48 0.00 0.00 103.59 5.19
75 61 M R 3.0 g bLF 0.30 0.06 0.47 0.10 179.24 1.63 100.01 7.52
76 56 M R 3.0 g bLF 0.14 0.43 0.01 0.00 114.75 1.33 116.55 9.73
77 64 M L 3.0 g bLF 7.21 1.59 0.00 0.00 12.60 2.78 151.89 6.20
78 56 F L 3.0 g bLF 2.52 0.57 23.60 4.57 0.00 0.00 61.92 1.97
79 69 M L 3.0 g bLF 5.65 1.25 0.00 0.00 192.10 0.58 20.10 3.54
79 69 M R 3.0 g bLF 7.69 0.80 6.24 1.16 177.28 0.54 173.96 8.99
80 66 M R 3.0 g bLF 1.30 0.86 6.49 0.19 0.46 1.39 46.45 8.28
81 60 M L 3.0 g bLF 10.37 2.38 100.08 7.02 0.00 0.00 13.10 2.38
82 73 M R 3.0 g bLF 3.63 0.83 64.39 5.39 0.00 0.00 84.47 4.47
83 62 M R 3.0 g bLF 1.11 1.27 0.17 0.04 0.25 0.56 65.94 11.10
84 62 M L 3.0 g bLF 0.00 0.00 13.47 1.85 133.61 0.19 124.60 3.76
85 65 M R 3.0 g bLF 0.00 0.00 120.80 7.59 0.00 0.00 132.71 5.70
86 48 M L 3.0 g bLF 2.11 0.48 0.02 0.02 71.96 1.82 0.00 0.00
86 48 M R 3.0 g bLF 1.22 1.40 0.00 0.00 0.00 0.00 47.65 8.15
87 70 F R 3.0 g bLF 0.00 0.00 116.97 6.02 0.00 0.00 9.17 1.80
88 69 M R 3.0 g bLF 0.03 0.09 12.24 3.45 0.35 1.07 123.61 4.21
89 70 M R 3.0 g bLF 9.35 1.60 5.11 0.92 0.02 0.05 108.55 10.70
90 59 M R 3.0 g bLF 1.84 1.94 0.00 0.00 0.08 0.25 30.48 6.11
91 70 M L 3.0 g bLF 0.00 0.00 100.46 6.05 0.00 0.00 0.08 0.02
92 50 F R 3.0 g bLF 0.26 0.78 6.47 1.18 0.00 0.00 23.72 3.80
93 67 F R 3.0 g bLF 7.16 1.38 46.06 1.64 0.00 0.00 74.01 12.42
94 66 M L 3.0 g bLF 0.04 0.13 0.00 0.00 1.16 1.32 116.88 6.68
95 64 M L 3.0 g bLF 0.00 0.00 80.95 14.80 0.11 0.32 53.68 9.36
95 64 M R 3.0 g bLF 20.40 4.52 0.00 0.00 0.00 0.00 1.16 0.27
88 69 M L 3.0 g bLF 0.01 0.04 11.59 2.24 NA NA NA NA
96 45 M L 3.0 g bLF 0.03 0.09 2.76 0.10 NA NA NA NA
96 45 M R 3.0 g bLF 0.00 0.00 0.00 0.00 NA NA NA NA
97 58 M L 3.0 g bLF 0.03 0.09 12.86 2.34 NA NA NA NA
98 66 M R 3.0 g bLF 9.94 2.28 64.34 4.05 NA NA NA NA
99 61 M L 3.0 g bLF NA NA NA NA 0.00 0.00 123.32 9.33
100 72 M L 3.0 g bLF NA NA NA NA 0.13 0.39 45.18 8.30
101 69 M R 3.0 g bLF NA NA NA NA 0.20 0.60 37.57 5.50
102 72 M L 3.0 g bLF NA NA NA NA 0.03 0.09 18.75 3.13
R: Right colon (cecum to transverse colon).







































than 10 had significantly (p < 0.001) higher IFNA expression
(64.8 ± 48.0) than samples in which the relative expression of
IFNB was less than 10 (IFNA = 31.1 ± 37.7).
Figure 1 shows the mean level of expression of IFNB and
IFNA in the placebo, 1.5 g bLF, and 3.0 g bLF groups before and
at the end of the trial.The mean and standard deviation of the
relative expression of IFNB is 11.2 ± 20.6 (placebo before),
8.6 ± 19.9 (placebo after), 24.7 ± 39.3 (1.5 g bLF before), 12.6 ± 26.3
(1.5 g bLF after), 2.8 ± 4.6 (3.0 g bLF before), and 27.6 ± 60.2 (3.0 g
bLF after). The relative expression of IFNB after ingesting 3.0 g
bLF for 1 year is significantly increased compared to its ex-
pression before the beginning of the trial (p = 0.027).The mean
and standard deviation of the relative expression of IFNA is
31.1 ± 36.3 (placebo before), 39.5 ± 37.1 (placebo after), 30.9 ± 42.6
(1.5 g bLF before), 47.1 ± 44.8 (1.5 g bLF after), 25.4 ± 38.3 (3.0 g
bLF before), and 67.2 ± 48.5 (3.0 g bLF after). The relative ex-
pression of IFNA after ingesting 3.0 g bLF for 1 year is signifi-
cantly increased compared to its expression before the
beginning of the trial (p < 0.001).
For each tissue sample-couplet (i.e., the sample collected
from a patient before the beginning of the trial and the sample
from that patient at the end of the trial) the relative expres-
sion of IFNB and IFNA in the sample collected at the end of
the trial period was compared with the relative expression of
IFNB and IFNA in the sample collected prior to the beginning
of the trial. Only sample-couplets from which β-actin was suc-
cessfully amplified in all TaqMan PCRs from the sample col-
lected prior to the beginning of the trial and the associated
sample collected at the end of the trial were used for this analy-
sis: β-actin was successfully amplified in 37 of the 38 placebo
group sample-couplets, in 35 of the 43 1.5 g bLF group sample-
couplets, and in 28 of the 37 3.0 g bLF group sample-couplets.
Due to the detection limit of the Applied Biosystems 7300 Real
Time System, a two-fold change in IFN expression was used
as the limit of detection for a change in IFN expression, i.e., if
IFN expression at the end of the trial period changed by less
than two-fold when compared to its expression prior to the
beginning of the trial period, then IFN expression was judged
to be unchanged.Also, when associated samples both had rela-
tive values below 0.1, interferon expression was judged to be
unchanged.
In the placebo group, expression of IFNB was increased by
two-fold or more in 13 (35%) of the sample-couplets, de-
creased by two-fold or more in 17 (49%) of the sample-couplets,
and unchanged in seven (19%) of the sample couplets. In the
1.5 g bLF group, expression of IFNB was increased by more than
two-fold in 16 (46%) of the sample-couplets, decreased by two-
fold or more in 13 (37%) of the sample-couplets, and un-
changed in six (17%) of the sample couplets. In the 3.0 g bLF
group, expression of IFNB was increased by more than two-
fold in 10 (36%) of the sample-couplets, decreased by two-
fold or more in 10 (36%) of the sample-couplets, and unchanged
in eight (29%) of the sample couplets. There was no signifi-
cant difference in the distribution of IFNB expression between
any of the trial groups.
In contrast to IFNB, there was a significant difference in the
distribution of IFNA expression between the 3.0 g bLF group
and the placebo and 1.5 g bLF groups. Figure 2 is a graphical
representation of the fold-induction of IFNA expression at the
end of the trial period in the placebo group (1A), 1.5 g bLF group
(1B), and 3.0 g bLF group (1C). In the placebo group, expres-
sion of IFNA was increased by two-fold or more in 18 (49%) of
the sample-couplets, decreased by two-fold or more in 15 (41%)
of the sample-couplets, and unchanged in four (11%) of the
sample couplets. In the 1.5 g bLF group, expression of IFNA was
increased by more than two-fold in 14 (40%) of the sample-
couplets, decreased by two-fold or more in six (17%) of the
sample-couplets, and unchanged in 15 (43%) of the sample
couplets. In the 3.0 g bLF group, expression of IFNA was in-
creased by more than two-fold in 20 (71%) of the sample-
couplets, decreased by two-fold or more in three (11%) of the
sample-couplets, and unchanged in five (19%) of the sample
couplets. There was no significant difference in the distribu-
tion of IFNA expression between the 1.5 g bLF and the placebo
groups (p = 0.4619); however, there was a significant differ-
ence in the distribution of IFNA expression in the 3.0 g bLF group
compared to the 1.5 g bLF group (p = 0.0409) and the placebo
group (p = 0.0173).
Figure 3 shows the relative expression of IFNB (2A) and IFNA
(2B) in trial participants who did not ingest bLF (placebo-
before, placebo-after, 1.5 g bLF-before, 3.0 g bLF before) and the
relative expression of IFNB and IFNA in the 3.0 g bLF group at
the end of the trial. As can be seen, the proportion of trial par-
ticipants with low expression of IFNA (for example, relative ex-
pression less than 10) in their colon tissue samples is markedly
less in the group that ingested bLF.
Fig. 1 – Relative levels of IFNB and IFNA at the beginning
and end of the Tokyo-trial. (A) Relative levels of IFNB in
tissue samples collected at the beginning, B, and after the
end, A, of the Tokyo-trial from the placebo (P), 1.5 g bLF, and
3.0 g bLF group participants. Levels of IFNB were
significantly higher in the 3.0 g bLF group after ingesting
3.0 g bLF daily for 1 year. (B) Relative levels of IFNA in
tissue samples collected at the beginning, B, and after the
end, A, of the Tokyo-trial from the placebo (P), 1.5 g bLF, and
3.0 g bLF group participants. Levels of IFNA were
significantly higher in the 3.0 g bLF group after ingesting
3.0 g bLF daily for 1 year.
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4. Discussion
In the clinical trial referred to in this report (the Tokyo-trial),
participants ingested 0, 1.5, or 3.0 g bLF for 1 year to deter-
mine whether ingestion of bLF had an effect on the growth of
colorectal polyps in humans (this trial is reported by Kozu et al.,
2009). The present study used normal tissue samples col-
lected from the Tokyo-trial participants before the trial began
and after the trial ended to determine if a change in the ex-
pression of one or more cytokines could be detected in the colon
of the Tokyo-trial participants who ingested bLF.
To identify cytokines for analysis, we initially screened
samples from the 3.0 g bLF group, the group that had a re-
sponse to ingestion of bLF. In this preliminary screening IFNG,
IL-4, IL-7, IL-8, IL-12A, IL-12B, IL-15, IL-18, IL-22, IL-23A, GM-
CSF, and TNF were either not detected or detected in a small
number of samples. Lack of detection of these cytokines was
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not unexpected: An important point is that patients diag-
nosed as having diseased or infected colons were excluded from
the Tokyo-trial. Consequently, the colons of the trial partici-
pants would not have excessive numbers of activated immune
cells secreting cytokines. A second point is that the intestine
is a dynamic and heterogeneous environment, with the mucosa
constantly interacting with food antigens and the intestinal
flora, and therefore, cytokine expression in the intestine is ex-
pected to differ at different sites and at different times. A third
point is that in a human trial, unlike animal studies in which
the entire intestine can be examined, only very small tissue
samples are available for examination.The tissue samples ex-
amined in this study had a colon mucosal surface area of less
than 10 mm2. In order for a cytokine to be detected in a ma-
jority of samples, it would have to be transcribed in a major-
ity of 10 mm2 sections of the colon. This is unlikely in the
normal human colon for most cytokines. Lack of detection of
expression of these cytokines made it impossible to deter-
mine whether or not ingestion of bLF affected their expres-
sion in the colon of theTokyo-trial participants; therefore, these
cytokines were not examined further.
In contrast to the other cytokines, expression of type I IFN
mRNA was detected in most of the samples from the 3.0 g bLF
group.Type I interferons are widespread immune systemmodu-
lators, and, unlike other cytokines, type I interferons can be
expressed by all known nucleated cells (Hervas-Stubbs et al.,
2011; Mancuso et al., 2007; Pichlmair & Reis e Sousa, 2007;
Theofilopoulos, Baccala, Beutler, & Kono, 2005; Trinchieri, 2010).
The samples were subsequently screened by standard end-
point PCR for the presence of the different type I interferons
(IFNB and the 13 species of human IFNA (Pestka, 2007)), fol-
lowed by sequencing of the PCR-generated amplicons to confirm
the identification of the interferon. IFNA2 sequences were
present in most of the tissue samples. IFNB sequences, while
less widespread than IFNA, were present in more than 50% of
the samples. The other IFNA species were either not identi-
fied by amplicon sequencing or their sequences were present
in only a minority of samples.Therefore, we examined the rela-
tive expression of IFNA2 and IFNB by TaqMan Real-Time PCR
using the primers listed in Supplementary Table S1.
Patients ingesting 3.0 g bLF for 1 year had a significant in-
crease in IFNB expression in the colon. However, this math-
ematically significant increase does not appear to reflect a
physiologically significant increase. As can be seen from
Tables 1–3, detection of IFNB was sporadic. Relative expres-
sion values greater than 10 for IFNB are observed in less than
25% of the samples. In addition, the mean expression level in
the colons of the 3.0 g bLF group before the trial began (mean
relative expression = 2.8) is significantly lower than in the 1.5 g
bLF group (mean relative expression = 24.7; p = 0.0016) and the
placebo group (mean relative expression = 11.2; p = 0.0192).This
suggests that the increase seen in IFNB expression after 1 year
in the 3.0 g bLF group may be due to the low level of IFNB ex-
pression in the samples collected prior to the beginning of the
trial. Notably, when the relative expression of IFNB in all pa-
tients which had not ingested bLF (placebo-before, placebo-
after, 1.5 g bLF-before, 3.0 g bLF-before) are combined (mean
relative expression = 12.2), there is only a non-significant in-
crease in the expression of IFNB in the 3.0 group at the end
of the trial (mean relative expression = 27.6; p = 0.1632).
Patients ingesting 3.0 g bLF for 1 year also had a signifi-
cant increase in IFNA expression in the colon. In contrast to
IFNB expression, relative expression values greater than 10 for
IFNA2 are observed in more than 50% of the samples. In ad-
dition, the mean expression level in the colons of the 3.0 g bLF
group before the trial began (mean relative expression = 25.4)
is not significantly different from the 1.5 g bLF group (mean
relative expression = 30.9; p = 0.5665) or the placebo group (mean
relative expression = 31.1; p = 0.5245). Moreover, when the rela-
tive expression of IFNA in all patients who had not ingested
bLF (placebo-before, placebo-after, 1.5 g bLF-before, 3.0 g bLF-
before) are combined (mean relative expression = 31.9), there
is a significant increase in the expression of IFNA in the 3.0
group at the end of the trial (mean relative expression = 67.2;
p = 0.0004).
The change in the distribution of IFNB and IFNA expres-
sion (decreased, no change, or increased) supports the pro-
posal that ingestion of bLF promotes the expression if IFNA,
but does not support the proposal that ingestion of bLF pro-
motes the expression of IFNB. The intestinal environment is
constantly changing due to the substances we eat and drink
and because of the interaction of the intestinal flora with the
intestinal mucosa (Artis, 2008; O’Hara & Shanahan, 2006).
Intestinal epithelial cells (IECs) and immune cells express a wide
range of pattern recognition receptors (PRRs) that can recog-
nize microbial factors such as lipopolysaccharide,
Fig. 2 – Fold-induction of IFNA expression after daily ingestion of placebo, 1.5 g bLF, or 3 g bLF for 1 year. The relative
expression of IFNA in the tissue sample collected at the end of the trial was compared with its relative expression in the
associated sample collected at the beginning of the trial. Reduction of IFN expression is calculated as the negative inverse
of the change in the expression of IFN [–1/(IFN-after/IFN-before)]; thus, if the relative expression of IFN at the end of the trial
was 25% of its expression at the start of the trial, the fold-induction is −4. Because the expression of IFNA in several of the
samples was very low or non-detectable, extremely large induction/reduction values were obtained in these sample-
couplets; therefore, a 10-fold increase or decrease in expression is used as a cut-off for the fold-induction of IFNA in this
figure. When associated samples both had relative values below 0.1, expression of IFNA was judged to be unchanged. (A)
Fold-induction of IFNA expression at the end of the trial period in the placebo group. (B) Fold-induction in IFNA expression
at the end of the trial period in the 1.5 g bLF group. (C) Fold-induction in IFNA expression at the end of the trial period in
the 3 g bLF group. There was a significant difference in the distribution of IFNA expression in the 3.0 g bLF group compared
to the 1.5 g bLF group (p = 0.0409) and the placebo group (p = 0.0173). The distribution of IFNA expression in the 1.5 g bLF
and the placebo groups was not significantly different (p = 0.4619). Patient numbers correspond to those in Tables 1–3, and
Supplementary Table S2.
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lipoproteins, flagellin, and unmethylated CpG-containing DNA
(Abreu, Fukata, & Arditi, 2005; Artis, 2008; Hall et al., 2008; O’Hara
& Shanahan, 2006; Yrlid et al., 2006). Therefore, signaling
through these receptors will change in accordance with the
intestinal environment. Consequently, the expression levels of
genes which are expressed by IECs and immune cells and which
respond to PRR signaling, such as type I interferons (Kawai &
Akira, 2010; Kawai et al., 2004; Paun et al., 2008; Takeuchi &
Akira, 2010; Yrlid et al., 2006), will fluctuate. In a population
composed of a random grouping of individuals, this fluctua-
tion is expected to appear random, resulting in an increase in
expression in about half of the population with detectable
cytokine expression and a decrease in expression in about half
of the population with detectable cytokine expression.This is
the result seen in the placebo group for both IFNA and IFNB.
In the 3 g bLF group, in contrast to the placebo group, IFNA ex-
pression was increased by more than two-fold in most of the
participants and only a few participants exhibited decreased
IFNA expression.The distribution of IFNA expression in the 3.0 g
bLF group was significantly different from the placebo group
(p = 0.0173). This is the result expected if ingestion of bLF pro-
moted expression of IFNA. In contrast to IFNA expression, there
Fig. 3 – Relative levels of IFNB and IFNA in Tokyo-trial participants who did not ingest bLF and Tokyo-trial participants who
ingested 3.0 g bLF daily for 1 year. (A) Relative levels of IFNB in trial participants who did not ingest bLF (placebo-before,
placebo-after, 1.5 g bLF-before, 3.0 g bLF before) and trial participants who ingested 3.0 g bLF daily for 1 year. (B) Relative
levels of IFNA in trial participants who did not ingest bLF (placebo-before, placebo-after, 1.5 g bLF-before, 3.0 g bLF before)
and trial participants who ingested 3.0 g bLF daily for 1 year.
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was no significant difference in the distribution of IFNB ex-
pression between the 3.0 g bLF group and the placebo (or 1.5 g
bLF) group.Therefore, while it is possible that ingestion of bLF
promoted IFNB expression in the colon, our overall results can
not be used to support this conclusion.
The Tokyo-trial reported that ingestion of 3 g bLF inhib-
ited the growth of colorectal polyps and increased the levels
of hLF in the serum of trial participants 63 years old or younger
(Kozu et al., 2009). Induction of IFNA in the human colon and
consequent IFNA-mediated suppression of cell growth (Bekisz,
Baron, Balinsky, Morrow, & Zoon, 2010) and IFNA-mediated
priming of neutrophils (Brassard, Grace, & Bordens, 2002;
Hervas-Stubbs et al., 2011; Theofilopoulos et al., 2005) is a plau-
sible mechanism by which ingestion of bLF mediated these
effects in theTokyo-trial participants. For the interested reader,
this hypothetical model, the results of theTokyo-trial, and why
the effects were age-dependent is discussed in detail in
Supplementary Text S2. Also discussed in Supplementary
Text S2 is the evidence that neither bLF itself nor bLF-derived
peptides exerted direct toxic effects against colorectal polyps
in the Tokyo-trial.
In a related study by Iigo et al. (2014), using Tokyo-trial
samples prepared for histological analysis, we found that par-
ticipants ingesting 3.0 g bLF had increased numbers of CD4+
cells and NK cells in their colorectal polyps. The increase in
polyp-associated CD4+ cells is consistent with the increase of
peritumoral and intratumoral CD4+ cells seen 15 days after
intralesional injection of basal cell carcinomas with IFNA
(Mozzanica et al., 1990) and suggest that induction of IFNA in
the colons of participants ingesting 3.0 g bLF resulted in an in-
crease of CD4+ cells in the colon mucosa and, consequently,
in the colorectal polyps of these trial participants. The in-
crease in polyp-associated NK cells is consistent with IFNA-
mediated induction of the expression of CXCL10 (Lande et al.,
2003), which is chemotactic for NK cells (Lande et al., 2003;
Megjugorac, Young, Amrute, Olshalsky, & Fitzgerald-Bocarsly,
2004).While the target polyps in the Tokyo-trial were precan-
cerous, and consequently were not targeted by the immune
system, the presence of increased numbers of CD4+ cells and
NK cells will enhance the ability of the immune system to target
and remove cells when they become transformed into cells with
increased tumorigenic potential. Taken together, our results
combined with the data discussed above suggest that promo-
tion of IFNA expression increases the responsiveness of the
immune system.
The ability of bLF to prime immune effector cells means that
the health benefits of ingesting bLF go beyond its protective
effects against cancer. By priming the immune system, inges-
tion of bLF is able to enhance the immune response against
the myriad diseases and infections to which humans are
subject. In support of this possibility, a recent study reports that
daily ingestion of 600 mg of a bLF/whey protein Ig-rich frac-
tion combination significantly decreased the occurrence of colds
reported and decreased the number of cold-related symp-
toms (Vitetta et al., 2013). This effect may be of particular im-
portance in the elderly whose immune function is declining.
It should be noted, however, that the model we propose in
Supplementary Text S2 suggests that for people with reduced
gastric digestive capability, predigested bLF may be a more ben-
eficial dietary supplement than bLF.
Consumption of LF by adult mammals has effects distinct
from those of endogenous LF. Endogenous LF is present at mod-
erate to high levels in tear film, upper airway fluids, seminal
fluid, and in the specific granules of neutrophils and is in-
volved in mucosal and neutrophil-mediated immunity (re-
viewed in Alexander, Iigo, Yamauchi, Suzui, & Tsuda, 2012).The
primary function of endogenous LF in mucosal fluids is to
promote the non-lethal, non-inflammatory removal of micro-
bial pathogens away from cells and tissues. Our model, as dis-
cussed in Supplementary Text S2, predicts that the differences
in the activities of ingested and endogenous LF in the adult
are due to the differences in the activities of the lactoferrin
protein and the antimicrobial peptides derived from gastric di-
gestion of lactoferrin.This paradigm is consistent with the pro-
posed activities of other bioactive peptides liberated by
gastrointestinal digestion of milk proteins (Korhonen, 2009).
It should be noted that the effects of the consumption of LF
by infants and adults are also distinct: Because lactoferrin is
highly resistant to digestion in the infant GI tract, LF in the
milk ingested by infants will have little microbicidal activity
and will function primarily as a microbiostatic agent promot-
ing the non-lethal, non-inflammatory removal of microbial
pathogens away from the intestinal epithelium (see Alexander
et al., 2012).
A major limitation of our study is the small number of
samples analyzed. Consequently, while significance was ob-
tained, follow up studies with a larger number of partici-
pants is needed to confirm our results. In addition, this study
used samples obtained from human volunteers; consequently:
(i) Tissue samples were not obtained from the small intes-
tine; therefore, the effect of bLF on cytokine production in the
small intestine and in Peyer’s Patches was not assessed. (ii)
While we show that ingestion of bLF promoted expression of
IFNA2 RNA in the colon of theTokyo-trial participants, the size
of the tissue samples and the number of samples was too small
to rigorously assess the effect of ingestion of bLF on the ex-
pression of other cytokines. (iii) Tissue samples for protein ex-
traction were not available; therefore, expression of IFNA protein
in the colon could not be analyzed.
Importantly, in all of the animal and human studies con-
ducted to date, which include chronic administration to animals
and daily intake for 1 year by human patients, no adverse events
related to ingestion of lactoferrin have been reported. In trials
with patients with chronic hepatitis C, 15 patients were given
3.6 g bLF for 6 months (Iwasa et al., 2002), 15 patients were given
7.2 g bLF daily for 8 weeks (Okada et al., 2002), and 97 pa-
tients were given 1.8 g bLF daily for 12 weeks (Ueno et al., 2006).
No adverse events related to bLF ingestion were reported by
any of these trials. In a clinical trial to determine whether in-
gestion of bLF had an effect on colorectal polyp growth, in-
gestion of 3.0 g bLF daily for 1 year had no adverse effects on
the trial participants (Kozu et al., 2009). Four long term cancer
survivors with metastatic renal cell carcinoma receiving re-
combinant human lactoferrin at a dose of 9 g per day given
in cycles of 2 weeks on/2 weeks off for 30 months or longer
showed no adverse events related to lactoferrin (Lewis & Hayes,
2011). Finally, the European Food Safety Authority (EFSA) Panel
on Dietetic Products, Nutrition and Allergies (NDA) has con-
cluded that intake of bLF up to 3.4 g per day by an adult is safe
(EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA),
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2012).Taken together, these data indicate that ingestion of bLF
is safe. However, the effects of consuming higher amounts of
lactoferrin than noted here are unknown and should be avoided.
5. Conclusions
Trial participants ingested 0, 1.5, or 3.0 g bLF for 1 year. Our
ancillary study found a significant increase in IFNB expres-
sion in the colons of the participants ingesting 3.0 g bLF;
however, the overall expression of IFNB in the trial partici-
pants and the distribution of IFNB expression (decreased, no
change, or increased) in the 3.0 g bLF group preclude conclud-
ing that this mathematically significant increase is physiologi-
cally significant. Our study also found a significant increase
in IFNA expression in the colons of the 3.0 bLF group, and the
overall expression of IFNA in the trial participants and the dis-
tribution of IFNA expression (decreased, no change, or in-
creased) in the 3.0 g bLF group supports the conclusion that
ingestion of 3.0 g bLF for 1 year resulted in increased expres-
sion of IFNA in the human colon. Our study validates the results
obtained from animal studies: ingestion of bLF promotes ex-
pression of immune modulating cytokines in the intestine.
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